The BIOKÉ webshop is under construction until January 2nd, 2017. We wish you a successful 2017!
NEBNext Direct® employs a unique technology that enables highly specific target enrichment of genomic regions of interest. The result of a partnership between New England Biolabs® (NEB®) and Directed Genomics™, this innovative approach to target enrichment balances the speed and precision of multiplexed PCR-based approaches with the content scalability typical of hybridization-based methods. This flexibility allows a single workflow for assays ranging from single gene tests to comprehensive panels including several hundred genes. Regardless of sample type or assay content, NEBNext Direct allows you to enrich your targets with precision. Read what other people are saying.
View our tutorial for help visualizing NEBNext Directs's unique and enabling workflow:
"NEBNext Direct enrichment technology is by far the fastest and most automation friendly protocol available today. I can have samples on the sequencer in 6 hours starting from genomic DNA. The technology produces very high on target percentages (>90%) for even very small panels, and in combination with molecular barcoding produces low duplication rates. From an optimization perspective, NEBNext Direct enrichment allows me to assign individual captured fragments to a probe unambiguously, thus giving the opportunity for optimizing the coverage distribution of any target."
– Eric C. Olivares, Founder, SEQanswers.com
"Using the NEBNext Direct kit, we were able to detect all known single nucleotide variants and indels in DNA extracted from fresh frozen or FFPE tissue derived from glioma biopsies. We could also clearly see amplification in genes like EGFR or PDGFR. The workflow is really easy and fast and can be rapidly implemented in a lab."
– Yannick Marie, Sequencing Core Facility Manager, Brain and Spine Institute (ICM)
"The kit and its technology are easy to use and easy to automate, allowing us to get up and running quickly. The protocol itself is fast and efficient to obtain deep coverage of targets, giving homogeneous results for FFPE and frozen tumors, therefore opening doors for customized panels."
– Francis Rousseau, Ph.D. Director of Genomics for IntegraGen SA